Ocular surface components

The ocular surface components constitute a complex, integrated functional unit that includes the cornea, conjunctiva, lacrimal glands, meibomian glands, and the overlying tear film (StatPearls, 2023). This system is essential for maintaining optical clarity, providing a smooth refractive surface for vision, and serving as a protective barrier against environmental pathogens and mechanical trauma (TFOS DEWS II, 2017). Ocular surface disease, particularly dry eye disease, arises when the homeostasis of this unit is disrupted, often involving a cycle of tear film instability, hyperosmolarity, and ocular surface inflammation (PubMed, PMID: 28736335). Therapeutic strategies do not target the ocular surface as a single molecule but rather address specific pathways within its components, such as inhibiting T-cell activation or enhancing lipid secretion to restore the tear film's protective properties (NIH, 2023). Consequently, while the ocular surface is a critical therapeutic area, it is defined by a collection of tissues and physiological processes rather than a single molecular target.

Other names

Ocular surfaceOcular surface systemCorneal-conjunctival unitLacrimal functional unit

Drugs targeting the ocular surface system act through various mechanisms including inhibition of T-cell mediated inflammation (Cyclosporine), antagonism of lymphocyte function-associated antigen-1 (Lifitegrast), activation of the trigeminal parasympathetic pathway to increase tear production (Varenicline), and stabilization of the tear film lipid layer (Perfluorohexyloctane).